Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1228281-54-6

ethyl 5-aMino-2-broMothiazole-4-carboxylate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1228281-54-6 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1228281-54-6 Structure

  • Basic information

    1. Product Name: ethyl 5-aMino-2-broMothiazole-4-carboxylate
    2. Synonyms: ethyl 5-aMino-2-broMothiazole-4-carboxylate;Methyl 5-aMinothiazole-4-carboxylate
    3. CAS NO:1228281-54-6
    4. Molecular Formula: C6H7BrN2O2S
    5. Molecular Weight: 251.10098
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1228281-54-6.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: ethyl 5-aMino-2-broMothiazole-4-carboxylate(CAS DataBase Reference)
    10. NIST Chemistry Reference: ethyl 5-aMino-2-broMothiazole-4-carboxylate(1228281-54-6)
    11. EPA Substance Registry System: ethyl 5-aMino-2-broMothiazole-4-carboxylate(1228281-54-6)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1228281-54-6(Hazardous Substances Data)

1228281-54-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1228281-54-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,8,2,8 and 1 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1228281-54:
(9*1)+(8*2)+(7*2)+(6*8)+(5*2)+(4*8)+(3*1)+(2*5)+(1*4)=146
146 % 10 = 6
So 1228281-54-6 is a valid CAS Registry Number.

1228281-54-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name Ethyl 5-amino-2-bromo-1,3-thiazole-4-carboxylate

1.2 Other means of identification

Product number -
Other names ethyl 5-amino-1-naphthoate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1228281-54-6 SDS

1228281-54-6Relevant articles and documents

Design, synthesis, in vitro evaluation of a new pyrrolo[1,2-a]thiazolo[5,4-d]pyrimidinone derivatives as cholinesterase inhibitors against Alzheimer's disease

Aisa, Haji Akber,Bozorov, Khurshed,Li, Yi,Liu, Liu,Nie, Lifei,Niu, Chao,Shen, Jingshan,Zeng, Yan,Zhao, Jiangyu

, (2022/02/16)

A novel of 40 pyrrolo[1,2-a]thiazolo[5,4-d]pyrimidinone derivatives were designed and synthesized as cholinesterase inhibitor agents. The in vitro enzyme assays proved that most of the compounds effectively inhibited cholinesterases in the micromolar rang

NOVEL BICYCLIC THIAZOLE COMPOUNDS

-

Paragraph 0122-0124, (2013/12/04)

The present invention relates to novel bicyclic thiazole compounds that inhibit Traf2- and Nck-interacting kinase (TNIK), and as such are useful as TNIK inhibitors administered to cancer patients, especially to solid cancer patients such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer or breast cancer. The bicyclic thiazole compounds are showed by a next formula (I). (wherein R1, R2, R3 and Q are as defined in the specification), or a pharmaceutically acceptable salt thereof.

TNIK INHIBITOR AND THE USE

-

Page/Page column 35, (2010/06/16)

The present invention relates to compositions and methods for the treatment of cancer patients with Traf2- and Nck-interacting kinase (TNIK) inhibitors. More particularly, the present invention relates to pharmaceutical compositions comprising TNIK inhibitor and a pharmaceutically acceptable carrier, and to methods for treating the TNIK inhibitor administered to cancer patients, especially to solid cancer patients such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer or breast cancer. And the present invention relates to a novel aminothiazole derivatives.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1228281-54-6